← Leaderboards
Herbert Wanjala Kavunja
Iaso Therapeutics, Inc.
$894,562
Attributed
$894,562
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300K · FY2020–22$500K$375K$250K$125K$0
'20
'21
'22
Funding mix
By agency
NIH$894,562 · 2
By mechanism
R43$894,562 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Immunoglobulin G”
- Hanjoon Ryu$28,519,898
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,144,108
- Wilton B Williams · Duke University$12,701,969
- Stylianos Bournazos · Rockefeller University$8,462,360
- Taia Wang · Stanford University$7,573,882
- Norbert Pardi · University Of Pennsylvania$7,042,071
Research focus
Immunoglobulin GMichiganHead-To-Head ComparisonImmunogenicityLicensingMediationCarbohydratesFightingImmune ResponseImmunogenicAntibodiesAntigensAntigen TargetingMalignant NeoplasmsBacteriophagesAntibody ResponseBaseEpitopesClinical ResearchImmuneImmunizeChemosensitizationBiotechnologyMouse Model
Grant awards (3)
Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine$294,562
R43 · FY2022 · AI · contact PI
Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine$300,000
R43 · FY2021 · AI · contact PI
A Novel Vaccine Strategy to Target Breast Cancer Enabled by Proprietary Mutant Bacteriophage Qbeta-Tumor Antigen Conjugates$300,000
R43 · FY2020 · CA · contact PI